NCT06556264View on ClinicalTrials.gov

Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Rhinosinusitis With Nasal PolypsAsthma
Interventions
DRUG

Dupilumab

Dupilumab 300mg every 2 weeks for 24 weeks

OTHER

Placebo

Placebo 300mg every 2 weeks for 24 weeks

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Dr. Andrew Thamboo, MD

OTHER

NCT06556264 - Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps | Biotech Hunter | Biotech Hunter